CYP51A1

Lanosterol 14-alpha demethylase · Q16850 · CYP51A1 on Sugi Atlas →

21,208 patent compounds predicted against CYP51A1, 15,254 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1322509	0.51	11/20
SCHEMBL906187	0.46	6/20
SCHEMBL1401593	0.49	4/20
Terconazole (SCHEMBL23165)	1.00	3/20
Itraconazole (SCHEMBL23934)	1.00	3/20
Itraconazole (SCHEMBL23935)	1.00	3/20
Itraconazole (SCHEMBL64913)	1.00	3/20
Itraconazole (SCHEMBL95627)	1.00	3/20
Itraconazole (SCHEMBL301223)	1.00	3/20
Terconazole (SCHEMBL1066299)	0.89	3/20
SCHEMBL1151809	0.83	3/20
SCHEMBL1152357	0.82	3/20
SCHEMBL1152907	0.82	3/20
Itraconazole (SCHEMBL1058775)	0.80	3/20
Saperconazole (SCHEMBL65701)	0.79	3/20
Itraconzole (SCHEMBL65702)	0.79	3/20
Itraconazole (SCHEMBL359857)	0.74	3/20
Itraconazole (SCHEMBL503873)	0.74	3/20
Terconazole (SCHEMBL1008228)	0.70	3/20
SCHEMBL1152599	0.70	3/20

Clinical trials — most relevant to CYP51A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
LDL Receptor Under Ezetimibe and Simvastatin	PHASE4	COMPLETED
Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.	PHASE4	RECRUITING
Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis	PHASE3	UNKNOWN
Efficacy and Safety of Terbinafine and Itraconazole	PHASE2/PHASE3	UNKNOWN
Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy	PHASE3	COMPLETED
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy	PHASE3	COMPLETED
Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis	PHASE2	COMPLETED
A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)	PHASE2	COMPLETED
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer	PHASE2	RECRUITING
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19	PHASE2	UNKNOWN
Smith-Lemli-Opitz Syndrome and Cholic Acid	PHASE1/PHASE2	COMPLETED
AMG 386 and Abiraterone for Advanced Prostate Cancer	PHASE2	COMPLETED
Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer	PHASE2	COMPLETED
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer	PHASE2	COMPLETED
The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients	PHASE2	UNKNOWN
Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor	PHASE1	COMPLETED
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer	PHASE1	RECRUITING
Alcohol Inhibits Drug Metabolism by Carboxylesterases	PHASE1	COMPLETED
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
Phase 1 Study of ATRS-2002 in Healthy Male Adults	PHASE1	WITHDRAWN
Fractional CO₂ Laser or 40% Urea With Topical Fluconazole Microemulsion in Onychomycosis	nan	NOT_YET_RECRUITING
Epidemiological and Molecular Analysis of Scalp Ringworm in France	nan	COMPLETED
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Mutation Analysis of 17α-Hydroxylase	nan	UNKNOWN
Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patients	nan	UNKNOWN
Fungal Infections in Patients With Hematological Malignancies	nan	UNKNOWN
Genetic Study of Sitosterolemia	nan	COMPLETED
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole	nan	WITHDRAWN
A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment	nan	UNKNOWN
Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP51A1 binder may also engage these)

Protein	Name	Similarity
Q4R8S6	—	1.000	Q4R8S6 →
Q5RE72	—	1.000	Q5RE72 →
O46420	—	1.000	O46420 →
Q4PJW3	—	1.000	Q4PJW3 →
Q64654	—	1.000	Q64654 →
Q8K0C4	—	1.000	Q8K0C4 →
Q1JPY5	—	0.997	Q1JPY5 →
B8N2C8	—	0.993	B8N2C8 →
Q4WNT5	—	0.992	Q4WNT5 →
A0A0L1JEW4	—	0.991	A0A0L1JEW4 →
B8NUK6	—	0.990	B8NUK6 →
O14442	—	0.989	O14442 →
P0DXU9	—	0.985	P0DXU9 →
B8NFL5	—	0.985	B8NFL5 →
E9QY26	—	0.984	E9QY26 →
I1RJR2	—	0.984	I1RJR2 →
Q12664	—	0.984	Q12664 →
I1RBR4	—	0.981	I1RBR4 →
I1S2M5	—	0.978	I1S2M5 →
P10614	—	0.976	P10614 →
P14263	—	0.976	P14263 →
P0DXV0	—	0.975	P0DXV0 →
O64698	—	0.974	O64698 →
P46634	—	0.973	P46634 →
A0A098DJ84	—	0.972	A0A098DJ84 →
Q09736	—	0.972	Q09736 →
Q02315	—	0.972	Q02315 →
Q64505	—	0.971	Q64505 →
CYP7A1	Cytochrome P450 7A1	0.969	landscape →
O64697	—	0.969	O64697 →